Skip to content

Amber Blair listen


Amber* is an associate at Lenczner Slaght with a broad intellectual property litigation practice. With a master's degree in materials chemistry and having worked as a marketing specialist at a large biotechnology company, Amber brings a deep understanding to the issues facing our clients. Thanks to her technical expertise, Amber knows§ how to make sense of complicated issues in cases dealing with everything from pharmaceuticals to telecommunications to oil and gas. No matter the complexity of the problem at hand, you can count on Amber to understand what matters most to her clients so she can provide the best solution to any problem. .



Amber Blair (she/her)

is an associate at Lenczner Slaght.

Amber's developing practice includes a broad range of intellectual property and commercial litigation. Amber has experience with disputes involving companies in the pharmaceuticals, biotechnology, life sciences, chemistry, telecommunications, technology, and oil and gas sectors.

Prior to joining Lenczner Slaght, Amber practiced in the intellectual property litigation group at a large international firm in Calgary and summered and articled at a leading national intellectual property boutique.

Before law school, Amber earned her BSc in chemistry from Saint Mary's University and her MSc in chemistry from the University of British Columbia. Amber's master’s research focused on designing innovative ways to increase the efficiency of dye-sensitized solar cells. After that, Amber worked as a chemistry instructor at Simon Fraser University and as a marketing specialist at a major Canadian biotechnology company.

Show more
  • Law Society of Ontario

  • Ontario Bar Association

  • Shocking Result? Summary Trial on Battery Jump Starter Patent Fails to Get Going

    Patent infringement cases are complex and technical, and historically Canadian courts were reluctant to endorse summary disposition in the patent context. However, in recent years there has been an increased trend towards the application of summary proceedings in this area. In particular, we have previously commented on decisions of the Federal Court (“FC”) (Canmar, Kobold, and Janssen) and Federal Court of Appeal (“FCA”) (Canmar and ViiV) that demonstrate the Court’s willingness to approve summary proceedings in patent cases under the appropriate circumstances. Last fall, the FCA decision in Gemak was interpreted by some commentators as a return to the historical position, but in our view, Gemak can be viewed as tapping the brakes on summary judgment rather than signalling a more sweeping reversal of the trend towards summary adjudication.

    Andrew Moeser & Amber Blair | May 4, 2023

  • To Consolidate or Not to Consolidate – This is the Federal Court’s Question

    In a recent decision, Takeda Canada Inc v Apotex Inc, the Federal Court dismissed the Plaintiff, Takeda’s, motion for consolidation of two actions against Apotex relating to Takeda’s dexlansoprazole (DEXILANT) under section 6 of the Patented Medicines (Notice of Compliance) Regulations (the “PM(NOC) Regulations”).

    Jordana Sanft, Andrew Moeser & Amber Blair | January 30, 2023

Back to top